Public release date: 9-Jan-2008
[ Print Article | E-mail Article | Close Window ]
Contact: Dottie Jeffries
djeffries@apsa.org
212-752-0450 x29
American Psychoanalytic Association
Uses of medications in psychoanalysis Potential benefits and drawbacks
As Americans increasingly seek a “quick fix” to physical and mental ailments, psychoanalysts can be caught in the crossfire of a debate about the potential benefits and drawbacks of including medication in their treatment plans. A panel discussion entitled, “The Uses of Medications in Psychoanalysis: What We Know; What is Uncertain,” will be led by internationally renowned psychoanalyst Glen O. Gabbard, M.D., at the American Psychoanalytic Association’s 2008 Winter Meeting. The panel discussion will be held on Friday, January 18, 2008, from 2-5 p.m. at the Waldorf Astoria Hotel in New York. Media are invited to attend.
Taking the position for a cautious approach to the inclusion of medications in analysis will be Stephen D. Purcell, M.D., whose paper titled “The Analyst’s Attitude toward Pharmacotherapy” will be published in the Journal of the American Psychoanalytic Association (JAPA) in 2008. Adele Tutter, M.D., Ph.D., is more optimistic about the inclusion of medications in treatment and her article, “Medication as Object,” was published in JAPA. The panel discussion will be chaired by Richard M. Gottlieb, M.D., and the discussant will be Dr. Gabbard.
“Instead of perceiving the use of medications in competition with analysis, we should educate our patients about the potential costs and benefits of including medication in an analytic treatment. Then, patients can make informed decisions about their treatment options,” says Dr. Tutter. “While we analysts value insight and introspection, some patients don’t value these things and should be allowed to choose.”
“I’m not taking the position that combined treatments that include medication and analysis should not be done. Instead, I believe they must be considered very carefully,” says Dr. Purcell. “An analyst’s decision to combine medication with a psychoanalysis is also a tacit communication that under some circumstances can be an interference to psychoanalytic processes of change.” The panel discussion is open to members of the media, mental health practitioners, students, and the public.
###
Media must email Dottie Jeffries at djeffries@apsa.org to obtain a press pass.
For a complete listing of sessions open to the press, visit http://www.apsa.org/Portals/1/docs/Meetings/SessionsOpentoPress1-4.pdf
Press releases related to the Meeting are available at http://www.apsa.org/MEETINGSANDEVENTS/PRESSRELEASES/tabid/445/Default.aspx
The American Psychoanalytic Association is a professional organization of psychoanalysts throughout the United States and is comprised of approximately 3,500 members. The Winter Meeting of the American Psychoanalytic Association is intended for the continuing education of the members and other registrants.
Visit www.apsa.org for more information.